Mitiglinide calcium hydrate (BioDeep_00000859128)

   


代谢物信息卡片


Mitiglinide calcium hydrate

化学式: C38H52CaN2O8 (704.3349382000001)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)[O-].C1CCC2CN(CC2C1)C(=O)CC(CC3=CC=CC=C3)C(=O)[O-].O.O.[Ca+2]
InChI: +2

描述信息

D007004 - Hypoglycemic Agents

同义名列表

1 个代谢物同义名

Mitiglinide calcium hydrate



数据库引用编号

3 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Kenji Akahane, Kazuma Ojima, Ayaka Yokoyama, Toshihiro Inoue, Sumiyoshi Kiguchi, Satoshi Tatemichi, Hiroo Takeda, Yohsuke Imai. Effects of combination of mitiglinide with various oral antidiabetic drugs in streptozotocin-nicotinamide-induced type 2 diabetic rats and Zucker fatty rats. Clinical and experimental pharmacology & physiology. 2017 Dec; 44(12):1263-1271. doi: 10.1111/1440-1681.12823. [PMID: 28744906]
  • Shijia Liu, Peidong Chen, Yang Zhao, Guoliang Dai, Bingting Sun, Yao Wang, Anwei Ding, Wenzheng Ju. Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers. BMC pharmacology & toxicology. 2017 07; 18(1):54. doi: 10.1186/s40360-017-0161-6. [PMID: 28676080]
  • Kenji Akahane, Kazuma Ojima, Ayaka Yokoyama, Toshihiro Inoue, Sumiyoshi Kiguchi, Satoshi Tatemichi, Hiroo Takeda, Mamoru Kobayashi. Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes. Drug research. 2017 Jul; 67(7):396-403. doi: 10.1055/s-0043-102951. [PMID: 28486736]
  • S Tani, K Nagao, A Hirayama. Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study. Drug research. 2016 Feb; 66(2):94-9. doi: 10.1055/s-0035-1549993. [PMID: 26011816]
  • Angela M Abbatecola, Mario Bo, Fabio Armellini, Ferdinando D'Amico, Giovambattista Desideri, Paolo Falaschi, Antonio Greco, Gianbattista Guerrini, Fabrizia Lattanzio, Clelia Volpe, Giuseppe Paolisso. Tighter glycemic control is associated with ADL physical dependency losses in older patients using sulfonylureas or mitiglinides: Results from the DIMORA study. Metabolism: clinical and experimental. 2015 Nov; 64(11):1500-6. doi: 10.1016/j.metabol.2015.07.018. [PMID: 26318195]
  • K Akahane, T Inoue, A Yokoyama, A Yaguchi, K Ojima, S Kiguchi, K Maruyama, M Kobayashi, Y Mori. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats. Drug research. 2015 Aug; 65(8):416-21. doi: 10.1055/s-0034-1387719. [PMID: 25188606]
  • Jang-Won Son, In-Kyu Lee, Jeong-taek Woo, Sei Hyun Baik, Hak Chul Jang, Kwan Woo Lee, Bong Soo Cha, Yeon-Ah Sung, Tae Sun Park, Soon-Jib Yoo, Kun-Ho Yoon. A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes. Endocrine journal. 2015; 62(12):1049-57. doi: 10.1507/endocrj.ej15-0325. [PMID: 26411328]
  • Takeshi Osonoi, Miyoko Saito, Atsuko Tamasawa, Hidenori Ishida, Yusuke Osonoi. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study. Expert opinion on pharmacotherapy. 2014 Jul; 15(10):1325-35. doi: 10.1517/14656566.2014.920323. [PMID: 24866329]
  • Yingtong Zeng, Xingqian Xie, Jingjing Duan, Ting Zhou, Ye Zhang, Min Yang, Feng Xu. Perturbation of mitiglinide metabolism by chronic unpredicted mild stress in rats. Scientific reports. 2014 Jan; 4(?):3794. doi: 10.1038/srep03794. [PMID: 24445843]
  • Tsuyoshi Ohkura, Kazuoki Inoue, Youhei Fujioka, Risa Nakanishi, Hideki Shiochi, Keisuke Sumi, Naoya Yamamoto, Kazuhiko Matsuzawa, Shoichiro Izawa, Hiroko Ohkura, Masahiko Kato, Kazuhiro Yamamoto, Shin-ichi Taniguchi. The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study. BMC research notes. 2013 Nov; 6(?):453. doi: 10.1186/1756-0500-6-453. [PMID: 24215809]
  • Jin Ah Jung, Kohei Kaku, Jae Hyeon Kim, Jung-Ryul Kim, Jae-Wook Ko, Soo-Youn Lee, Wooseong Huh. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus. Advances in therapy. 2013 Nov; 30(11):1018-29. doi: 10.1007/s12325-013-0072-x. [PMID: 24249434]
  • Haley M Phillippe, Kurt A Wargo. Mitiglinide for type 2 diabetes treatment. Expert opinion on pharmacotherapy. 2013 Oct; 14(15):2133-44. doi: 10.1517/14656566.2013.834048. [PMID: 23992284]
  • Fuminori Tatsumi, Mitsuru Hashiramoto, Hidenori Hirukawa, Tomohiko Kimura, Masashi Shimoda, Kazuhito Tawaramoto, Yukiko Kanda-Kimura, Takatoshi Anno, Fumiko Kawasaki, Tomoatsu Mune, Michihiro Matsuki, Kohei Kaku. Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus. Diabetes research and clinical practice. 2013 Jul; 101(1):35-44. doi: 10.1016/j.diabres.2013.04.007. [PMID: 23711593]
  • Jin Ah Jung, Jung-Ryul Kim, Suk-Ran Kim, Tae-Eun Kim, Soo-Youn Lee, Jae-Wook Ko, Wooseong Huh. Pharmacokinetics of a fixed-dose combination of mitiglinide and metformin versus concurrent administration of individual formulations in healthy subjects: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover study. Clinical drug investigation. 2012 Dec; 32(12):799-804. doi: 10.1007/s40261-012-0012-6. [PMID: 23100167]
  • Masahiro Inoue. Tighter control of postprandial hyperglycemia with mitiglinide/voglibose fixed-dose combination in Japanese patients with type 2 diabetes mellitus. Expert opinion on pharmacotherapy. 2012 Nov; 13(16):2257-68. doi: 10.1517/14656566.2012.726614. [PMID: 22994875]
  • Lisa Kitasato, Taiki Tojo, Yuko Hatakeyama, Ryo Kameda, Takehiro Hashikata, Minako Yamaoka-Tojo. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Cardiovascular diabetology. 2012 Jun; 11(?):79. doi: 10.1186/1475-2840-11-79. [PMID: 22748110]
  • Hind Hadi, Ahmad Makahleh, Bahruddin Saad. Hollow fiber liquid-phase microextraction combined with high performance liquid chromatography for the determination of trace mitiglinide in biological fluids. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 May; 895-896(?):131-6. doi: 10.1016/j.jchromb.2012.03.031. [PMID: 22503735]
  • Toshiyuki Takanohashi, Harumi Arisaka, Kazuyuki Ubukata, Masahiro Hayashi, Yasuhiko Yamada. Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats. European journal of drug metabolism and pharmacokinetics. 2012 Mar; 37(1):9-15. doi: 10.1007/s13318-011-0068-3. [PMID: 22012638]
  • Bo Wang, Gangyi Yang, Mengliu Yang, Yong Liao, Zhiyong Li, Guenther Boden, Ling Li. Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM. Cytokine. 2012 Feb; 57(2):300-3. doi: 10.1016/j.cyto.2011.11.002. [PMID: 22129626]
  • J Zhang, L-J Cai, W-X Peng, R-H Zhu, J Yang, Q-Z Zhang. The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. Journal of clinical pharmacy and therapeutics. 2012 Feb; 37(1):95-9. doi: 10.1111/j.1365-2710.2011.01257.x. [PMID: 21517925]
  • L Jin, Q Cao. Effect of gemfibrozil on the pharmacokinetics of mitiglinide in rats. Arzneimittel-Forschung. 2012 Jan; 62(1):40-5. doi: 10.1055/s-0031-1295425. [PMID: 22331762]
  • Masanori Abe, Kazuyoshi Okada, Takashi Maruyama, Noriaki Maruyama, Koichi Matsumoto. Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert opinion on pharmacotherapy. 2010 Feb; 11(2):169-76. doi: 10.1517/14656560903530683. [PMID: 20025554]
  • Masanori Abe, Kazuyoshi Okada, Takashi Maruyama, Noriaki Maruyama, Koichi Matsumoto. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocrine journal. 2010; 57(7):579-86. doi: 10.1507/endocrj.k09e-318. [PMID: 20467165]
  • H Konya, M Miuchi, K Konishi, E Nagai, T Ueyama, Y Kusunoki, Y Kimura, Y Nakamura, T Ishikawa, C Inokuchi, T Katsuno, T Hamaguchi, J Miyagawa, M Namba. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. The Journal of international medical research. 2009 Nov; 37(6):1904-12. doi: 10.1177/147323000903700628. [PMID: 20146890]
  • Shuang Cai, Taoguang Huo, Jinghua Xu, Xiumei Lu, Shuning Zheng, Famei Li. Effect of mitiglinide on Streptozotocin-induced experimental type 2 diabetic rats: a urinary metabonomics study based on ultra-performance liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Nov; 877(29):3619-24. doi: 10.1016/j.jchromb.2009.08.044. [PMID: 19748326]
  • Kohei Kaku, Shun-ichi Tanaka, Hideki Origasa, Masatoshi Kikuchi, Yasuo Akanuma. Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. Endocrine journal. 2009; 56(5):657-64. doi: 10.1507/endocrj.k09e-022. [PMID: 19352048]
  • Kohei Kaku, Shun-Ichi Tanaka, Hideki Origasa, Masatoshi Kikuchi, Yasuo Akanuma. Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. Endocrine journal. 2009; 56(6):739-46. doi: 10.1507/endocrj.k09e-023. [PMID: 19506328]
  • Willy J Malaisse. Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert opinion on pharmacotherapy. 2008 Oct; 9(15):2691-8. doi: 10.1517/14656566.9.15.2691. [PMID: 18803455]
  • Yan Zhang, Likun Ding, Yun Tian, Jing Yang, Lin Yang, Aidong Wen. Liquid chromatography/electrospray ionization tandem mass spectrometry for the quantification of mitiglinide in human plasma: validation and its application to pharmacokinetic studies. Biomedical chromatography : BMC. 2008 Aug; 22(8):873-8. doi: 10.1002/bmc.1005. [PMID: 18318018]
  • Shuang Cai, Taoguang Huo, Wanyu Feng, Lingyun Chen, Feng Qin, Famei Li. Quantitative determination of mitiglinide in human plasma by ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2008 Jun; 868(1-2):83-7. doi: 10.1016/j.jchromb.2008.04.037. [PMID: 18486570]
  • Jiabi Liang, Yuan Tian, Zunjian Zhang, Shudan Feng, Yanan Zhao, Guoguang Mao. High-performance liquid chromatography-electrospray ionization mass spectrometry determination of mitiglinide in human plasma and its pharmacokinetics. Journal of mass spectrometry : JMS. 2007 Feb; 42(2):171-7. doi: 10.1002/jms.1139. [PMID: 17173338]
  • Yu Lushan, Zeng Su. Determination of mitiglinide in rat plasma by high-performance liquid chromatography with UV detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Apr; 834(1-2):204-7. doi: 10.1016/j.jchromb.2006.02.029. [PMID: 16520101]
  • Y Mori, K Ojima, Y Fuujimori, Y Fujimori, I Aoyagi, H Kusama, Y Yamazaki, M Kojima, S Kojima, N Shibata, Y Itoh, N Tajima. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Endocrine. 2006 Apr; 29(2):309-15. doi: 10.1385/endo:29:2:309. [PMID: 16785606]
  • R Assaloni, R Da Ros, L Quagliaro, L Piconi, A Maier, G Zuodar, E Motz, A Ceriello. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia. 2005 Sep; 48(9):1919-24. doi: 10.1007/s00125-005-1849-5. [PMID: 16007412]
  • Kazuma Ojima, Yuji Kiyono, Masami Kojima. [Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 2004 Oct; 124(4):245-55. doi: 10.1254/fpj.124.245. [PMID: 15467258]
  • Masato Odawara. [Nateglinide and mitiglinide]. Nihon rinsho. Japanese journal of clinical medicine. 2003 Jul; 61(7):1230-7. doi: . [PMID: 12877090]
  • Kiyoshi Ichikawa, Tokuhisa Yamato, Kazuma Ojima, Atsutoshi Tsuji, Kohtaro Ishikawa, Hiroshi Kusama, Masami Kojima. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clinical and experimental pharmacology & physiology. 2002 May; 29(5-6):423-7. doi: 10.1046/j.1440-1681.2002.03682.x. [PMID: 12010187]
  • K Misawa, K Ichikawa, K Ojima, S Hamano, T Kitamura, H Komatsu. Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs. Pharmacology. 2001 Feb; 62(2):65-72. doi: 10.1159/000056073. [PMID: 11174074]
  • M Kikuchi. [Non-SU, insulin secretagogues]. Nihon rinsho. Japanese journal of clinical medicine. 1999 Mar; 57(3):702-8. doi: NULL. [PMID: 10199157]
  • W J Malaisse, B Dard-Brunelle. Binding of tritiated S21403 to an artificial phospholipid bilayer. Research communications in molecular pathology and pharmacology. 1999 Mar; 103(3):269-74. doi: ". [PMID: 10509738]
  • H Ohnota, T Kitamura, M Kinukawa, S Hamano, N Shibata, H Miyata, A Ujiie. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Japanese journal of pharmacology. 1996 Aug; 71(4):315-23. doi: 10.1254/jjp.71.315. [PMID: 8886929]
  • L Lins, R Brasseur, W J Malaisse. Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family. Biochemical pharmacology. 1995 Nov; 50(11):1879-84. doi: 10.1016/s0006-2952(99)80003-3. [PMID: 8615868]
  • H Ohnota, T Koizumi, M Kobayashi, Y Momose, F Sato. Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats. Canadian journal of physiology and pharmacology. 1995 Jan; 73(1):1-6. doi: 10.1139/y95-001. [PMID: 7600439]
  • H Mogami, H Shibata, R Nobusawa, H Ohnota, F Satou, J Miyazaki, I Kojima. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell. European journal of pharmacology. 1994 Nov; 269(3):293-8. doi: 10.1016/0922-4106(94)90036-1. [PMID: 7895769]
  • H Ohnota, T Koizumi, N Tsutsumi, M Kobayashi, S Inoue, F Sato. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. The Journal of pharmacology and experimental therapeutics. 1994 May; 269(2):489-95. doi: NULL. [PMID: 8182516]